1147858-83-0

Basic information

• Product Name: 2,6-dibroMobenzyl acetate
• Synonyms: 2,6-dibroMobenzyl acetate;Acetic acid 2,6-dibromobenzyl ester
• CAS NO: 1147858-83-0
• Molecular Formula: C₉H₈Br₂O₂
• Molecular Weight: 307.96662
• EINECS: -0
• Mol File: 1147858-83-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 311.4±27.0 °C(Predicted)
• Appearance: /
• Density: 1.763±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2,6-dibroMobenzyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dibroMobenzyl acetate(1147858-83-0)
• EPA Substance Registry System: 2,6-dibroMobenzyl acetate(1147858-83-0)

Safety Data

• Hazardous Substances Data: 1147858-83-0(Hazardous Substances Data)

Usage

General Description

2,6-Dibromobenzyl acetate is a chemical compound with the molecular formula C9H8Br2O2. It is a white solid and is commonly used as a reagent in organic synthesis. 2,6-Dibromobenzyl acetate is often utilized as an intermediate in the production of pharmaceuticals, perfumes, and other fine chemicals. It can also be used as a building block in the synthesis of other organic compounds. 2,6-Dibromobenzyl acetate is known for its moderate toxicity and requires careful handling and disposal to avoid environmental and health hazards.

Upstream product

• 93701-32-7 2,6-dibromobenzyl bromide 
• 127-08-2 potassium acetate 
• 69321-60-4 2,6-dibromotoluene 
• 127-09-3 sodium acetate 

Downstream Products

• 1147858-84-1 2,6-diethylbenzyl acetate 
• 91967-55-4 2,6-diethylbenzyl alcohol 
• 1178884-69-9 acetic acid 2-bromo-6-(6-tert-butyl-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)-benzyl ester 
• 1178884-42-8 acetic acid 2-bromo-6-(6-dimethylamino-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl)benzyl ester 
• 1178884-38-2 acetic acid 2-bromo-6-(6-dimethylamino-1-oxo-1H-isoquinolin-2-yl)-benzyl ester 
• 1178884-48-4 acetic acid 2-bromo-6-[6-(ethyl-methyl-amino)-1-oxo-3,4-dihydro-1H-isoquinolin-2-yl]-benzyl ester 
• 1314879-43-0 C₂₁H₁₉BrFNO₃ 
• 1346674-00-7 2-bromo-6-(1-oxo-3,4,6,7,8,9-hexahydropyrido[3,4-b]imidazo[4,5-c]pyridine-2-yl)benzyl acetate 
• 1346672-74-9 2-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1346669-58-6 2-(2-(hydroxymethyl)-3-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346672-79-4 2-(1-oxo-3,4,5,6,7,8-hexahydrobenzothieno[2,3-c]pyridin-2(1H)-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1346669-60-0 5-[2-(hydroxymethyl)-3-[4-methyl-5-oxo-6-(pyridine-3-ylamino)-4,5-dihydropyrazin-2-yl]phenyl]-8-thia-5-azatricyclo[7.4.0.0(2,7)]trideca-1⁽⁹⁾,2⁽⁷⁾-dien-6-one 
• 1346669-61-1 2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-methyl-1H-pyrazol-3-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1360086-13-0 C₃₀H₃₂N₆O₄ 

Relevant articles and documents

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties

In our continued effort to discover and develop best-in-class Bruton's tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compounds that improved upon the druglike properties of our previous chemical matter. Compounds exemplified by G-744 are highly potent, selective for Btk, metabolically stable, well tolerated, and efficacious in an animal model of arthritis.

PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.